ReviewEngineering in life sciences2026
Transposon-derived genome editors in plants: from compact nucleases to large-fragment integration and regeneration strategies.
Review in Engineering in life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR/Cas technology has been transformative for genome editing, enabling the precise integration of large DNA fragments-a capability essential for advanced genome (re)writing in plants, such as for trait stacking and pathway engineering. However, several new RNA-guided systems derived from transposable elements (TEs) have shown promise for plant genome editing, thereby enriching the toolkit available for plant engineering. This review comprehensively analyzes these emerging TE-based editors, including OMEGA nucleases (TnpB, IscB, Fanzor), CRISPR-associated transposases (CASTs), and R2 retrotransposon-derived systems. We detail their distinct architectures, evolutionary origins, and unique advantages over traditional Cas9, such as their compact size, simplified guide RNAs, and staggered DNA cleavage. We critically evaluate their nascent applications in plant models, highlighting ongoing challenges in editing efficiency, delivery, and specificity. Notably, CASTs and R2 retrotransposon-derived systems show particular promise for programmable large-fragment DNA integration, offering potential solutions for next-generation plant genome writing applications. We also examine the critical link between genome editing and plant regeneration, discussing phytohormonal and morphogenic regulators (e.g., BBM, WUS), and innovative tissue-culture-free methods, such as Cut-Dip-Budding. By comparing their merits and limitations, we position these systems not as replacements but as complementary tools within an expanding genome-editing toolkit. Integrating optimized TE-based editors with robust regeneration strategies is poised to unlock new frontiers in plant synthetic biology and crop improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.